The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The significance of acid/base properties in drug discovery
Open accessAbstract
While drug discovery scientists take heed of various guidelines concerning drug-like character, the influence of acid/base properties often remains under-scrutinised. Ionisation constants (pK(a) values) are fundamental to the variability of the biopharmaceutical characteristics of drugs and to underlying parameters such as logD and solubility. pK(a) values affect physicochemical properties such as aqueous solubility, which in turn influences drug formulation approaches. More importantly, absorption, distribution, metabolism, excretion and toxicity (ADMET) are profoundly affected by the charge state of compounds under varying pH conditions. Consideration of pK(a) values in conjunction with other molecular properties is of great significance and has the potential to be used to further improve the efficiency of drug discovery. Given the recent low annual output of new drugs from pharmaceutical companies, this review will provide a timely reminder of an important molecular property that influences clinical success.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Structure and chemistry of cytochrome p450
Denisov, I. G., Makris, T. M., Sligar, S. G., & Schlichting, I. (2005) · Chemical Reviews · doi:10.1021/cr0307143 · Cited by 2,106
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
A Medicinal Chemist’s Guide to Molecular Interactions
Bissantz, C., Kuhn, B., & Stahl, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100112j · Cited by 1,731
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Crystal structure of human cytochrome P450 2C9 with bound warfarin
Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak Vinković, D., & Jhoti, H. (2003) · Nature · doi:10.1038/nature01862 · Cited by 821
Structural basis for ligand promiscuity in cytochrome P450 3A4
Ekroos, M., & Sjögren, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603236103 · Cited by 758
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Functional group contributions to drug-receptor interactions
Andrews, P. R., Craik, D. J., & Martin, J. L. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00378a021 · Cited by 535
A general pattern for substrate recognition by P‐glycoprotein
Seelig, A. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2510252.x · Cited by 527
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
The significance of mitochondrial toxicity testing in drug development
Dykens, J. A., & Will, Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.013 · Cited by 416
Cory Kalvass, J., & Maurer, T. S. (2002) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.325 · Cited by 412
Using the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion
Fischer, H., Gottschlich, R., & Seelig, A. (1998) · Journal of Membrane Biology · doi:10.1007/s002329900434 · Cited by 371
ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE
Schanker, L. S., Tocco, D. J., Brodie, B. B., & Hogben, C. A. M. (1958) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12018-1 · Cited by 371
Molecular obesity, potency and other addictions in drug discovery
Hann, M. M. (2011) · MedChemComm · doi:10.1039/c1md00017a · Cited by 363
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Chemical stability of pharmaceuticals
Connors, K. A., Amidon, G. L., & Stella, V. J. (1979) · Cited by 319
Classification Analysis of P-Glycoprotein Substrate Specificity
Didziapetris, R., Japertas, P., Avdeef, A., & Petrauskas, A. (2003) · Journal of Drug Targeting · doi:10.1080/10611860310001648248 · Cited by 253
Martin, Y. C. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9303-2 · Cited by 237
Compilation of 222 drugs’ plasma protein binding data and guidance for study designs
Zhang, F., Xue, J., Shao, J., & Jia, L. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.018 · Cited by 220
The Drug Transporter−Metabolism Alliance: Uncovering and Defining the Interplay
Benet, L. Z. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900253n · Cited by 205
Perola, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100118x · Cited by 188
A Novel Approach for Predicting P-Glycoprotein (ABCB1) Inhibition Using Molecular Interaction Fields
Broccatelli, F., Carosati, E., Neri, A., Frosini, M., Goracci, L., Oprea, T. I., & Cruciani, G. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101421d · Cited by 176
Self-citationPalm, K., Luthman, K., Ros, J., Gråsjö, J., & Artursson, P. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35123-7 · Cited by 173
Nadanaciva, S., Dykens, J. A., Bernal, A., Capaldi, R. A., & Will, Y. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.06.003 · Cited by 166
The influence of the 'organizational factor' on compound quality in drug discovery
Leeson, P. D., & St-Gallay, S. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3552 · Cited by 162
A quantitative assessment of hERG liability as a function of lipophilicity
Waring, M. J., & Johnstone, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.061 · Cited by 159
Peters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 156
Metabolic activation of carboxylic acids
Skonberg, C., Olsen, J., Madsen, K., Hansen, S. H., & Grillo, M. P. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.425 · Cited by 154
Lee, A. C., & Crippen, G. M. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900209w · Cited by 134
Predicting P-glycoprotein substrates by a quantitative structure–activity relationship model
Gombar, V. K., Polli, J. W., Humphreys, J. E., Wring, S. A., & Serabjit‐Singh, C. J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20035 · Cited by 112
Plasma Protein Binding Affinity and Its Relationship to Molecular Structure: An In-silico Analysis
Gleeson, M. P. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060981b · Cited by 107
Phospholipidosis as a Function of Basicity, Lipophilicity, and Volume of Distribution of Compounds
Hanumegowda, U., Wenke, G., Regueiro‐Ren, A., Yordanova, R., Corradi, J., & Adams, S. P. (2010) · Chemical Research in Toxicology · doi:10.1021/tx9003825 · Cited by 105
Impact of ion class and time on oral drug molecular properties
Leeson, P. D., St-Gallay, S. A., & Wenlock, M. C. (2010) · MedChemComm · doi:10.1039/c0md00157k · Cited by 87
Naven, R. T., Swiss, R. L., Klug-McLeod, J. L., Will, Y., & Greene, N. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs279 · Cited by 86
In Silico Human and RatVssQuantitative Structure−Activity Relationship Models
Gleeson, M. P., Waters, N. J., Paine, S. W., & Davis, A. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0510070 · Cited by 79
Improving the prediction of the brain disposition for orally administered drugs using BDDCS
Broccatelli, F., Larregieu, C. A., Cruciani, G., Oprea, T. I., & Benet, L. Z. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.008 · Cited by 78
Self-citationhERG-related drug toxicity and models for predicting hERG liability and QT prolongation
Raschi, E., Ceccarini, L., Ponti, F. D., & Recanatini, M. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903055070 · Cited by 77
The acid–base profile of a contemporary set of drugs: implications for drug discovery
Manallack, D. T. (2009) · SAR and QSAR in environmental research · doi:10.1080/10629360903438313 · Cited by 76
Self-citationEvaluation and Prediction of Drug Permeation
Pagliara, A., Reist, M., Geinoz, S., Carrupt, P., & Testa, B. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991777164 · Cited by 75
PHYSICOCHEMICAL AND CELL-BASED APPROACH FOR EARLY SCREENING OF PHOSPHOLIPIDOSIS-INDUCING POTENTIAL
Tomizawa, K., Sugano, K., Yamada, H., et al. (2006) · The Journal of Toxicological Sciences · doi:10.2131/jts.31.315 · Cited by 73
Critical Compilation of pKa Values for Pharmaceutical Substances
Prankerd, R. J. (2007) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/s0099-5428(07)33001-3 · Cited by 69
Self-citationFan, Y., Unwalla, R. J., Denny, R. A., Di, L., Kerns, E. H., Diller, D., & Humblet, C. C. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci900384c · Cited by 67
Development of Specific “Drug‐Like Property” Rules for Carboxylate‐Containing Oral Drug Candidates
Böcker, A., Bonneau, P. R., Hucke, O., Jakalian, A., & Edwards, P. J. (2010) · ChemMedChem · doi:10.1002/cmdc.201000355 · Cited by 42
Cited by
In silico ADME/T modelling for rational drug design
Wang, Y., Xing, J., Xu, Y., Zhou, N., Peng, J., Xiong, Z., Liu, X., Luo, X., Luo, C., Chen, K., et al. (2015) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583515000190 · Cited by 367
Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273
Advances in the physicochemical profiling of opioid compounds of therapeutic interest
Mazák, K., Noszál, B., & Hosztafi, S. (2019) · ChemistryOpen · doi:10.1002/open.201900115 · Cited by 27
Metadata
- Authors
- Manallack, D. T., Prankerd, R. J., Yuriev, E., Oprea, T. I., & Chalmers, D. K.
- Venue
- Chem. Soc. Rev.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2013
- Volume
- 42
- Issue
- 2
- Pages
- 485-496
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2086806820
- Cited by
- 329
- References
- 52
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
